Axiom Biosciences
Coverage of Axiom Biosciences in the Nexus archive.
- US biotech firm developing therapies for infant brain injuries plans Hong Kong listing
Axiom Biosciences, a US-based biotech firm developing AI-powered therapies for infant brain injuries, plans a primary Hong Kong IPO targeting $200 million in 2027, with a secondary US listing in 2029.
- US biotech firm developing therapies for infant brain injuries plans Hong Kong listing
A US-based biotech firm, Axiom Biosciences, plans to pursue a primary Hong Kong IPO in 2027 to raise at least US$200 million for its AI-driven therapies targeting infant brain injuries, with a secondary US listing planned for 2029. The company is part of a growing trend of AI-powered medical firms seeking capital in Hong Kong.
- US-Based Axiom Seeks Hong Kong IPO to Tap China’s Biotech Boom
Axiom Biosciences is considering a Hong Kong initial public offering, a rare move for an American biotechnology firm. The IPO aims to leverage China's growing clinical development capabilities in the biotech sector.